Evidence map›Paper›PMID 42312836›Full record

ArticleJournal of virology2026

Palmitoylation of CLDN12 regulated by ZDHHC7 and APT1/2 promotes hepatitis C virus entry.

Huiying Zhang, Yihan Liu, Ting Xu, Junwen Luan, Leiliang Zhang

Abstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Huiying ZhangDepartment of Clinical Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
Yihan LiuDepartment of Pathogen Biology, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Ting XuDepartment of Pathogen Biology, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Junwen LuanDepartment of Pathogen Biology, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Leiliang ZhangDepartment of Clinical Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.ORCID 0000-0002-7015-9661

Funding

Joint Innovation Team for Clinical & Basic Research 202409National Natural Science Foundation of China 82272306Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project 2025ZD01903602Shandong Provincial Natural Science Foundation ZR2024MH180Taishan Scholar Program tstp20221142
6 · The paper itself

Abstract

Hepatitis C virus (HCV) entry is a critical step in establishing infection and is highly dependent on host cell co-receptors. We previously identified that the tight junction protein CLDN12 facilitates HCV entry. However, the regulatory mechanisms governing the dynamic post-translational modifications of CLDN12 remain unclear. This study employs targeted mutagenesis, palmitoylation level analysis, plasma membrane localization, manipulation of key enzymes, and functional virology assays to reveal whether and how reversible palmitoylation regulates the function of CLDN12 in HCV entry. We found that the palmitoylation occurs at cysteine residues C3 and C109 of CLDN12, a modification critical for its role in mediating HCV entry. The palmitoyltransferase ZDHHC7 is a key enzyme that catalyzes the palmitoylation of CLDN12, positively promoting HCV entry. Acyl-protein thioesterases APT1 and APT2 regulate the de-palmitoylation of CLDN12 through differential modulation at the two sites, thereby negatively regulating HCV entry. Our study discovers that ZDHHC7 and APT1/2 form a reversible palmitoylation switch, which regulates the efficiency of HCV entry by dynamically controlling the plasma membrane localization of CLDN12. This finding reveals a new mechanism by which HCV exploits the host's palmitoylation cycle to promote infection, and highlights this regulatory axis as a potential target for antiviral intervention. IMPORTANCE: HCV infection poses a significant global health burden. Despite the remarkable efficacy of direct antiviral agents, developing new strategies targeting host factors is crucial for addressing drug resistance and re-infection. Viral entry is a key step in establishing infection, where the host factor CLDN12 promotes HCV invasion. However, the regulatory mechanisms controlling the plasma membrane localization of CLDN12 remain unclear. This study elucidates the mechanism of CLDN12 palmitoylation, regulated by the palmitoyltransferase ZDHHC7 and the acyl-protein thioesterases APT1 and APT2. This dynamic palmitoylation switch governs the plasma membrane localization and function of CLDN12 through reversible modifications, thereby regulating the efficiency of HCV entry. This discovery not only expands our understanding of the network of host palmitoylation regulatory mechanisms involved in HCV entry but also reveals a finely tuned dynamic equilibrium model characterized by the collaborative regulation of palmitoyltransferases and acyl-protein thioesterases, with a preference for specific sites.

Indexed as

AcyltransferasesClaudinsHepacivirusHepatitis CLipoylationThiolester HydrolasesVirus InternalizationCell LineCell MembraneHumansProtein Processing, Post-TranslationalAcyltransferasesClaudinsLYPLA1 protein, humanLYPLA2 protein, humanThiolester HydrolasesCLDN12hepatitis C viruspalmitoylationvirus entryZDHHC7

Identifiers

PMID42312836
PMCPMC13386948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.